Literature DB >> 23299492

Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.

Naomi Nakajima1, Yoshifumi Sugawara, Masaaki Kataoka, Yasushi Hamamoto, Takashi Ochi, Shinya Sakai, Tadaaki Takahashi, Makoto Kajihara, Norihiro Teramoto, Motohiro Yamashita, Teruhito Mochizuki.   

Abstract

OBJECTIVE: Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiotherapy (SBRT), is now a standard treatment option for patients with stage I non-small cell lung cancer or oligometastatic lung tumor who are medically inoperable or medically operable but refuse surgery. When mass-like consolidation is observed on follow-up CT after SABR, it is sometimes difficult to differentiate tumor recurrence from SABR-induced pulmonary fibrosis. In this study, we evaluated the role of (18)F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) in differentiating tumor recurrence from radiation fibrosis after SABR.
METHODS: Between June 2006 and June 2009, 130 patients received SABR for stage I non-small cell lung cancer or metastatic lung cancer at our institution. Fifty-nine patients of them were imaged with FDG-PET/CT after SABR. There were a total of 137 FDG-PET/CT scans for retrospective analysis. The FDG uptake in the pulmonary region was assessed qualitatively using a 3-point scale (0, none or faint; 1, mild; or 2, moderate to intense), and the shape (mass-like or non mass-like) was evaluated. For semi-quantitative analysis, the maximum standardized uptake value (SUV(max)) was calculated.
RESULTS: Sixteen of 59 patients had local failure. In recurrent tumor, the combination of intensity grade 2 and mass-like shape was most common (21/23; 91%). By contrast, in cases of radiation fibrosis, the combination of intensity grade 0 or 1 and non mass-like shape was most common (48/59; 81%). The SUV(max) of tumor recurrence after 12 months was significantly higher than that of radiation fibrosis (8.0 ± 3.2 vs. 2.1 ± 0.9, p < 0.001), and all tumor recurrence showed the SUV(max) > 4.5 at diagnosis of local failure. At ≥12 months after SABR, these two variables, the combination of intensity 2 and mass-like FDG uptake or SUV(max) > 4.5 acquired a significant high predictive value of local recurrence, finding sensitivity 100% and specificity 100% for both of them.
CONCLUSIONS: The combination of FDG uptake patterns and SUV(max) was useful for distinguishing tumor recurrence from radiation fibrosis after SABR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23299492     DOI: 10.1007/s12149-012-0682-4

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  21 in total

1.  Imaging texture analysis for automated prediction of lung cancer recurrence after stereotactic radiotherapy.

Authors:  Sarah A Mattonen; Shyama Tetar; David A Palma; Alexander V Louie; Suresh Senan; Aaron D Ward
Journal:  J Med Imaging (Bellingham)       Date:  2015-11-12

Review 2.  New techniques for assessing response after hypofractionated radiotherapy for lung cancer.

Authors:  Sarah A Mattonen; Kitty Huang; Aaron D Ward; Suresh Senan; David A Palma
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

Review 3.  Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?

Authors:  Sarah A Mattonen; Aaron D Ward; David A Palma
Journal:  Br J Radiol       Date:  2016-06-20       Impact factor: 3.039

4.  Early PET-CT After Stereotactic Radiotherapy for Stage 1 Non-small Cell Lung Carcinoma Is Predictive of Local Control.

Authors:  Marguerite Tyran; Nathalie Charrier; Julien Darreon; Anne Madroszyk; Agnes Tallet; Naji Salem
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

Review 5.  Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.

Authors:  Helen Cliffe; Chirag Patel; Robin Prestwich; Andrew Scarsbrook
Journal:  Br J Radiol       Date:  2017-01-30       Impact factor: 3.039

6.  Diagnosis of a growing radiation-induced skull lesion in a patient: an unusual scar.

Authors:  Andrea P Perera; Gautam U Mehta; Drew Pratt; Martha M Quezado; Mark R Gilbert; John D Heiss
Journal:  J Neurosurg       Date:  2015-12-18       Impact factor: 5.115

7.  Computed tomographic features predictive of local recurrence in patients with early stage lung cancer treated with stereotactic body radiation therapy.

Authors:  Darragh Halpenny; Carole A Ridge; Sara Hayes; Junting Zheng; Chaya S Moskowitz; Andreas Rimner; Michelle S Ginsberg
Journal:  Clin Imaging       Date:  2014-12-12       Impact factor: 1.605

8.  Can high-risk CT features suggest local recurrence after stereotactic body radiation therapy for lung cancer? A systematic review and meta-analysis.

Authors:  Tae-Hyung Kim; Sungmin Woo; Darragh F Halpenny; Yeon Joo Kim; Soon Ho Yoon; Chong Hyun Suh
Journal:  Eur J Radiol       Date:  2020-04-07       Impact factor: 3.528

9.  Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer?

Authors:  Megan E Daly; Laurel A Beckett; Allen M Chen
Journal:  Pract Radiat Oncol       Date:  2013-10-08

10.  18F-FLT PET/CT Adds Value to 18F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Cancer: Results of a Prospective Clinical Trial.

Authors:  Tine Nøhr Christensen; Seppo W Langer; Gitte Persson; Klaus Richter Larsen; Annika Loft; Annemarie Gjelstrup Amtoft; Anne Kiil Berthelsen; Helle Hjorth Johannesen; Sune Høgild Keller; Andreas Kjaer; Barbara Malene Fischer
Journal:  J Nucl Med       Date:  2020-10-09       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.